Informazioni sul sito:

Nome del dominio - iclepertin.it

Titolo del sito - iclepertin.it

Domain iclepertin.it viene reindirizzato a https://www.boehringer-ingelheim.com

Posizione GEO del sito

Posizione Paese - France

Fornitore - Nameshield SAS

Site Logo

indirizzo IP:

81.92.80.56 81.92.80.55

Server dei nomi di dominio:

ns3.nameshield.net obs.ns1.fr ns2.observatoiredesmarques.fr

Tutti i record:

☆ iclepertin.it. 21600 IN TXT "v=spf1 include:_spf.boehringer-ingelheim.com -all"
☆ iclepertin.it. 21600 IN A 81.92.80.56
☆ iclepertin.it. 21600 IN A 81.92.80.55
☆ iclepertin.it. 21600 IN MX 10 mail2.boehringer-ingelheim.com.
☆ iclepertin.it. 21600 IN MX 10 mail1.boehringer-ingelheim.com.
☆ iclepertin.it. 21600 IN MX 10 mail3.boehringer-ingelheim.com.
☆ iclepertin.it. 21600 IN MX 10 mail4.boehringer-ingelheim.com.
☆ iclepertin.it. 21600 IN NS obs.ns1.fr.
☆ iclepertin.it. 21600 IN NS ns3.nameshield.net.
☆ iclepertin.it. 21600 IN NS ns2.observatoiredesmarques.fr.
☆ iclepertin.it. 21600 IN SOA obs.ns1.fr. technical.nameshield.net. 2023012318 28800 7200 604800 7200

Brief facts about iclepertin:

Iclepertin is an investigational nootropic to enhance the cognition and functional capacity in schizophrenia developed by Boehringer Ingelheim. As of May 2020, it is in phase III of clinical trial under the code name CONNEX-3. BI 425809 is an inhibitor of glycine transporter 1 that in phase II improved cognition after 12 weeks in patients with schizophrenia. Doses of 10 mg and 25 mg showed the largest separation from placebo. If these encouraging results are confirmed in phase 3 trials, BI 425809 could provide an effective treatment for cognitive impairment associated with schizophrenia. Schizophrenia is characterized by abnormalities in glutamatergic pathways related to NMDA receptor hypofunction. Inhibition of GlyT1 on the presynaptic membrane or astrocytes is hypothesized to increase glycine levels within the synapse.

Glycine reuptake inhibitors

Oxazoles

Sulfones

Schizophrenia

Nootropics